Skip to main content
SpringerLink
Log in

Bullous Diseases: Old Blisters with New Therapeutic Targets

  • Chapter
  • First Online:
Personalized Treatment Options in Dermatology

  • 924 Accesses

Abstract

Immunobullous diseases are rare but potentially life threatening diseases that often require aggressive immunosuppression. While traditionally this has been in the form of broad immunosuppression with small-molecule drugs such as corticosteroids, newer therapies have arisen, targeting more specific pathways in the immunopathogenesis of the disease. We discuss the use of immunoadsorption, intravenous immunoglobulin, and rituximab in different bullous diseases, as well as the underlying mechanism behind these drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J. Bullous pemphigoid and pemphigus vulgaris–incidence and mortality in the UK: population based cohort study. BMJ. 2008;337:a180.

    PubMed Central  CAS  PubMed  Google Scholar 

  2. Beutner EH, Jordon RE. Demonstration of skin antibodies in sera of pemphigus vulgaris patients by indirect immunofluorescent staining. Proc Soc Exp Biol Med. 1964;117:505–10.

    CAS  PubMed  Google Scholar 

  3. Amagai M, Karpati S, Prussick R, Klaus-Kovtun V, Stanley JR. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest. 1992;90:919–26.

    PubMed Central  CAS  PubMed  Google Scholar 

  4. Amagai M, Nishikawa T, Nousari HC, Anhalt GJ, Hashimoto T. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J Clin Invest. 1998;102:775–82.

    PubMed Central  CAS  PubMed  Google Scholar 

  5. Amagai M, Karpati S, Klaus-Kovtun V, Udey MC, Stanley JR. Extracellular domain of pemphigus vulgaris antigen (desmoglein 3) mediates weak homophilic adhesion. J Invest Dermatol. 1994;103:609–15.

    CAS  PubMed  Google Scholar 

  6. Di Zenzo G, Di Lullo G, Corti D, et al. Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface. J Clin Invest. 2012;122:3781–90.

    PubMed Central  PubMed  Google Scholar 

  7. Ishii K, Amagai M, Hall RP, et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol. 1997;159:2010–7.

    CAS  PubMed  Google Scholar 

  8. Muller R, Svoboda V, Wenzel E, Muller HH, Hertl M. IgG against extracellular subdomains of desmoglein 3 relates to clinical phenotype of pemphigus vulgaris. Exp Dermatol. 2008;17:35–43.

    PubMed  Google Scholar 

  9. Amber KT, Staropoli P, Shiman MI, Elgart GW, Hertl M. Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris. Exp Dermatol. 2013;22:699–704.

    CAS  PubMed  Google Scholar 

  10. Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. J Clin Invest. 2006;116:1159–66.

    PubMed Central  CAS  PubMed  Google Scholar 

  11. Nagel A, Lang A, Engel D, et al. Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3. Clin Immunol. 2010;134:320–30.

    CAS  PubMed  Google Scholar 

  12. Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 2: diagnosis and therapy. J Dtsch Dermatol Ges. 2011;9:927–47.

    PubMed  Google Scholar 

  13. Hertl M, Jedlickova H, Karpati S et al. Pemphigus. S2 Guideline for diagnosis and treatment - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2014. doi: 10.1111/jdv.12772. [Epub ahead of print].

  14. Eming R, Hertl M. Immunoadsorption in pemphigus. Autoimmunity. 2006;39:609–16.

    CAS  PubMed  Google Scholar 

  15. Schmidt E, Zillikens D. Immunoadsorption in dermatology. Arch Dermatol Res. 2010;302:241–53.

    PubMed  Google Scholar 

  16. Schmidt E, Klinker E, Opitz A, et al. Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol. 2003;148:1222–9.

    CAS  PubMed  Google Scholar 

  17. Luftl M, Stauber A, Mainka A, Klingel R, Schuler G, Hertl M. Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol. 2003;149:598–605.

    CAS  PubMed  Google Scholar 

  18. Eming R, Rech J, Barth S, et al. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology. 2006;212:177–87.

    PubMed  Google Scholar 

  19. Gunther C, Laske J, Frind A, Julius U, Pfeiffer C. Successful therapy of pemphigus vulgaris with immunoadsorption using the TheraSorb adsorber. J Dtsch Dermatol Ges. 2008;6:661–3.

    PubMed  Google Scholar 

  20. Kasperkiewicz M, Shimanovich I, Meier M, et al. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol. 2012;166:154–60.

    CAS  PubMed  Google Scholar 

  21. Behzad M, Mobs C, Kneisel A, et al. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Br J Dermatol. 2012;166:844–52.

    CAS  PubMed  Google Scholar 

  22. Kasperkiewicz M, Eming R, Behzad M, et al. Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases. J Dtsch Dermatol Ges. 2012;10:727–32.

    PubMed  Google Scholar 

  23. Czernik A, Beutner EH, Bystryn JC. Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus. J Am Acad Dermatol. 2008;58:796–801.

    PubMed  Google Scholar 

  24. Herzog S, Schmidt E, Goebeler M, Brocker EB, Zillikens D. Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins. Acta Derm Venereol. 2004;84:48–52.

    CAS  PubMed  Google Scholar 

  25. Seidling V, Hoffmann JH, Enk AH, Hadaschik EN. Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events. Acta Derm Venereol. 2013;93:346–9.

    PubMed  Google Scholar 

  26. Sami N, Qureshi A, Ruocco E, Ahmed AR. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol. 2002;138:1158–62.

    CAS  PubMed  Google Scholar 

  27. Green MG, Bystryn JC. Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris. Arch Dermatol. 2008;144:1621–4.

    CAS  PubMed  Google Scholar 

  28. Amagai M, Ikeda S, Shimizu H, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol. 2009;60:595–603.

    PubMed  Google Scholar 

  29. Kuijpers TW, Bende RJ, Baars PA, et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest. 2010;120:214–22.

    PubMed Central  CAS  PubMed  Google Scholar 

  30. Rouziere AS, Kneitz C, Palanichamy A, Dorner T, Tony HP. Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody. Arthritis Res Ther. 2005;7:R714–24.

    PubMed Central  CAS  PubMed  Google Scholar 

  31. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:613–20.

    CAS  PubMed  Google Scholar 

  32. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357:545–52.

    CAS  PubMed  Google Scholar 

  33. Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol. 2008;128:2850–8.

    CAS  PubMed  Google Scholar 

  34. Muller R, Hunzelmann N, Baur V, et al. Targeted immunotherapy with rituximab leads to a transient alteration of the IgG autoantibody profile in pemphigus vulgaris. Dermatol Res Pract. 2010;2010:321950.

    PubMed Central  PubMed  Google Scholar 

  35. Reguiai Z, Tabary T, Maizieres M, Bernard P. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up. J Am Acad Dermatol. 2012;67:623–9.

    CAS  PubMed  Google Scholar 

  36. Mouquet H, Musette P, Gougeon ML, et al. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol. 2008;128:2859–69.

    CAS  PubMed  Google Scholar 

  37. Colliou N, Picard D, Caillot F, et al. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med. 2013;5:175ra130.

    Google Scholar 

  38. Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003;48:2146–54.

    PubMed  Google Scholar 

  39. Cambridge G, Isenberg DA, Edwards JC, et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis. 2008;67:1011–6.

    CAS  PubMed  Google Scholar 

  40. Teng YK, Wheater G, Hogan VE, et al. Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity. Arthritis Res Ther. 2012;14:R57.

    PubMed Central  CAS  PubMed  Google Scholar 

  41. Ferraro AJ, Drayson MT, Savage CO, MacLennan IC. Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab. Eur J Immunol. 2008;38:292–8.

    CAS  PubMed  Google Scholar 

  42. Nagel A, Podstawa E, Eickmann M, Muller HH, Hertl M, Eming R. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J Invest Dermatol. 2009;129:2202–10.

    CAS  PubMed  Google Scholar 

  43. Hall 3rd RP, Streilein RD, Hannah DL, et al. Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients. J Invest Dermatol. 2013;133:2786–8.

    CAS  PubMed  Google Scholar 

  44. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med. 2006;203:743–53.

    PubMed Central  CAS  PubMed  Google Scholar 

  45. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006;313:670–3.

    CAS  PubMed  Google Scholar 

  46. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44:3823–37.

    CAS  PubMed  Google Scholar 

  47. Golay J, Manganini M, Facchinetti V, et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica. 2003;88:1002–12.

    CAS  PubMed  Google Scholar 

  48. Fischer L, Penack O, Gentilini C, et al. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp Hematol. 2006;34:753–9.

    CAS  PubMed  Google Scholar 

  49. Bhat R, Watzl C. Serial killing of tumor cells by human natural killer cells–enhancement by therapeutic antibodies. PLoS One. 2007;2:e326.

    PubMed Central  PubMed  Google Scholar 

  50. Berdeja JG, Hess A, Lucas DM, et al. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin Cancer Res. 2007;13:2392–9.

    CAS  PubMed  Google Scholar 

  51. Lee CS, Ashton-Key M, Cogliatti S, et al. Expression of inhibitory Fc receptor (Fc?RIIB) is a marker of poor response to rituximab monotherapy in follicular lymphoma. Lancet. 2013;381:S63.

    Google Scholar 

  52. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6:443–6.

    CAS  PubMed  Google Scholar 

  53. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;125:232–9.

    CAS  PubMed  Google Scholar 

  54. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435–45.

    CAS  PubMed  Google Scholar 

  55. Bellosillo B, Villamor N, Lopez-Guillermo A, et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood. 2001;98:2771–7.

    CAS  PubMed  Google Scholar 

  56. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol. 2003;171:1581–7.

    PubMed  Google Scholar 

  57. Kennedy AD, Solga MD, Schuman TA, et al. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood. 2003;101:1071–9.

    CAS  PubMed  Google Scholar 

  58. Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003;101:1045–52.

    CAS  PubMed  Google Scholar 

  59. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004;103:2738–43.

    CAS  PubMed  Google Scholar 

  60. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95:3900–8.

    CAS  PubMed  Google Scholar 

  61. Treon SP, Mitsiades C, Mitsiades N, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother. 2001;24:263–71.

    CAS  Google Scholar 

  62. Golay J, Cittera E, Di Gaetano N, et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica. 2006;91:176–83.

    CAS  PubMed  Google Scholar 

  63. Klepfish A, Rachmilewitz EA, Kotsianidis I, Patchenko P, Schattner A. Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL. QJM. 2008;101:737–40.

    CAS  PubMed  Google Scholar 

  64. Lessey E, Li N, Diaz L, Liu Z. Complement and cutaneous autoimmune blistering diseases. Immunol Res. 2008;41:223–32.

    CAS  PubMed  Google Scholar 

  65. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91:1644–52.

    CAS  PubMed  Google Scholar 

  66. Chan HT, Hughes D, French RR, et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res. 2003;63:5480–9.

    CAS  PubMed  Google Scholar 

  67. Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol. 2008;20:444–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  68. Tsunoda K, Ota T, Suzuki H, et al. Pathogenic autoantibody production requires loss of tolerance against desmoglein 3 in both T and B cells in experimental pemphigus vulgaris. Eur J Immunol. 2002;32:627–33.

    CAS  PubMed  Google Scholar 

  69. Ujiie H, Shibaki A, Nishie W, et al. Noncollagenous 16A domain of type XVII collagen-reactive CD4+ T cells play a pivotal role in the development of active disease in experimental bullous pemphigoid model. Clin Immunol. 2012;142:167–75.

    CAS  PubMed  Google Scholar 

  70. Sitaru AG, Sesarman A, Mihai S, et al. T cells are required for the production of blister-inducing autoantibodies in experimental epidermolysis bullosa acquisita. J Immunol. 2010;184:1596–603.

    CAS  PubMed  Google Scholar 

  71. Bortnick A, Allman D. What is and what should always have been: long-lived plasma cells induced by T cell-independent antigens. J Immunol. 2013;190:5913–8.

    PubMed Central  CAS  PubMed  Google Scholar 

  72. Xu W, Banchereau J. The antigen presenting cells instruct plasma cell differentiation. Front Immunol. 2014;4:504.

    PubMed Central  PubMed  Google Scholar 

  73. Leshem Y A, David M, Hodak E, et al. A prospective study on clinical response and cell-mediated immunity of pemphigus patients treated with rituximab. Arch Dermatol Res. 2014;306(1):67–74.

    Google Scholar 

  74. Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol. 2007;123:66–73.

    CAS  PubMed  Google Scholar 

  75. Toubi E, Kessel A, Slobodin G, et al. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:818–20.

    PubMed Central  CAS  PubMed  Google Scholar 

  76. Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007;110:2924–30.

    CAS  PubMed  Google Scholar 

  77. Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood. 2008;112:1147–50.

    CAS  PubMed  Google Scholar 

  78. Vallerskog T, Gunnarsson I, Widhe M, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol. 2007;122:62–74.

    CAS  PubMed  Google Scholar 

  79. Feuchtenberger M, Muller S, Roll P, et al. Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Open Rheumatol J. 2008;2:81–8.

    PubMed Central  CAS  PubMed  Google Scholar 

  80. Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005;52:501–13.

    CAS  PubMed  Google Scholar 

  81. Wilk E, Witte T, Marquardt N, et al. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum. 2009;60:3563–71.

    CAS  PubMed  Google Scholar 

  82. Lunardon L, Payne AS. Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigus. J Allergy Clin Immunol. 2012;130:800–3.

    PubMed Central  PubMed  Google Scholar 

  83. Schmidt E, Hennig K, Mengede C, Zillikens D, Kromminga A. Immunogenicity of rituximab in patients with severe pemphigus. Clin Immunol. 2009;132:334–41.

    CAS  PubMed  Google Scholar 

  84. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940–7.

    CAS  PubMed  Google Scholar 

  85. Dall’Ozzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 2004;64:4664–9.

    PubMed  Google Scholar 

  86. Gamonet C, Ferrand C, Colliou N, et al. Lack of expression of an alternative CD20 transcript variant in circulating B cells from patients with pemphigus. Exp Dermatol. 2014;23:66–7.

    CAS  PubMed  Google Scholar 

  87. Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther. 2009;11:R123.

    PubMed Central  PubMed  Google Scholar 

  88. Amber KT, Hertl M. An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab. J Eur Acad Dermatol Venereol. 2014. doi: 10.1111/jdv.12678. [Epub ahead of print].

  89. Leshem YA, Hodak E, David M, Anhalt GJ, Mimouni D. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients. J Am Acad Dermatol. 2013;68:404–11.

    CAS  PubMed  Google Scholar 

  90. Balighi K, Daneshpazhooh M, Khezri S, Mahdavi-nia M, Hajiseyed-javadi M, Chams-Davatchi C. Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial. Int J Dermatol. 2013;52:862–7.

    PubMed  Google Scholar 

  91. Lunardon L, Tsai KJ, Propert KJ, et al. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol. 2012;148:1031–6.

    PubMed Central  CAS  PubMed  Google Scholar 

  92. Cianchini G, Lupi F, Masini C, Corona R, Puddu P, De Pita O. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol. 2012;67:617–22.

    CAS  PubMed  Google Scholar 

  93. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355:1772–9.

    CAS  PubMed  Google Scholar 

  94. Feldman RJ, Ahmed AR. Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses. Expert Rev Clin Immunol. 2011;7:529–41.

    CAS  PubMed  Google Scholar 

  95. Zakka LR, Shetty SS, Ahmed AR. Rituximab in the treatment of pemphigus vulgaris. Dermatol Ther (Heidelb). 2012;2:17.

    Google Scholar 

  96. Kanwar AJ, Vinay K, Sawatkar GU, et al. Clinical and immunological outcomes of high and low dose rituximab treatments in pemphigus patients: a randomized comparative observer blinded study. Br J Dermatol. 2014;170(6):1341–9.

    Google Scholar 

  97. Mimouni D, Nousari CH, Cummins DL, Kouba DJ, David M, Anhalt GJ. Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. J Am Acad Dermatol. 2003;49:1059–62.

    PubMed  Google Scholar 

  98. Leger S, Picard D, Ingen-Housz-Oro S, et al. Prognostic factors of paraneoplastic pemphigus. Arch Dermatol. 2012;148:1165–72.

    PubMed  Google Scholar 

  99. Vezzoli P, Berti E, Marzano AV. Rationale and efficacy for the use of rituximab in paraneoplastic pemphigus. Expert Rev Clin Immunol. 2008;4:351–63.

    CAS  PubMed  Google Scholar 

  100. Joly P, Richard C, Gilbert D, et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol. 2000;43:619–26.

    CAS  PubMed  Google Scholar 

  101. Schadlow MB, Anhalt GJ, Sinha AA. Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus. J Drugs Dermatol. 2003;2:564–7.

    PubMed  Google Scholar 

  102. Shetty S, Ahmed AR. Treatment of bullous pemphigoid with rituximab: critical analysis of the current literature. J Drugs Dermatol. 2013;12:672–7.

    CAS  PubMed  Google Scholar 

  103. Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, et al. Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol. 2011;147:843–9.

    PubMed  Google Scholar 

  104. Heelan K, Walsh S, Shear NH. Treatment of mucous membrane pemphigoid with rituximab. J Am Acad Dermatol. 2013;69:310–1.

    PubMed  Google Scholar 

  105. Shetty S, Ahmed AR. Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature. J Am Acad Dermatol. 2013;68:499–506.

    CAS  PubMed  Google Scholar 

  106. Niedermeier A, Eming R, Pfutze M, et al. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol. 2007;143:192–8.

    CAS  PubMed  Google Scholar 

  107. McKinley SK, Huang JT, Tan J, Kroshinsky D, Gellis S. A case of recalcitrant epidermolysis bullosa acquisita responsive to rituximab therapy. Pediatr Dermatol. 2014;31(2):241–4.

    Google Scholar 

  108. Cavailhes A, Balme B, Gilbert D, Skowron F. Successful use of combined corticosteroids and rituximab in the treatment of recalcitrant epidermolysis bullosa acquisita. Ann Dermatol Venereol. 2009;136:795–9.

    CAS  PubMed  Google Scholar 

  109. Schmidt E, Benoit S, Brocker EB, Zillikens D, Goebeler M. Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Arch Dermatol. 2006;142:147–50.

    PubMed  Google Scholar 

  110. Kim JH, Lee SE, Kim SC. Successful treatment of epidermolysis bullosa acquisita with rituximab therapy. J Dermatol. 2012;39:477–9.

    CAS  PubMed  Google Scholar 

  111. Kubisch I, Diessenbacher P, Schmidt E, Gollnick H, Leverkus M. Premonitory epidermolysis bullosa acquisita mimicking eyelid dermatitis: successful treatment with rituximab and protein A immunoapheresis. Am J Clin Dermatol. 2010;11:289–93.

    PubMed  Google Scholar 

  112. Saha M, Cutler T, Bhogal B, Black MM, Groves RW. Refractory epidermolysis bullosa acquisita: successful treatment with rituximab. Clin Exp Dermatol. 2009;34:e979–80.

    CAS  PubMed  Google Scholar 

  113. Sadler E, Schafleitner B, Lanschuetzer C, et al. Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab. Br J Dermatol. 2007;157:417–9.

    CAS  PubMed  Google Scholar 

  114. Crichlow SM, Mortimer NJ, Harman KE. A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita. Br J Dermatol. 2007;156:194–6.

    CAS  PubMed  Google Scholar 

  115. Ludwig RJ. Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita. ISRN Dermatol. 2013;2013:812029.

    PubMed Central  PubMed  Google Scholar 

  116. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222–33.

    CAS  PubMed  Google Scholar 

  117. Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol. 2010;130:2041–8.

    CAS  PubMed  Google Scholar 

  118. Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology. 2010;117:861–9.

    PubMed  Google Scholar 

  119. Ventura F, Rocha J, Fernandes JC, Machado A, Brito C. Recalcitrant pemphigus vulgaris: aseptic meningitis associated with intravenous immunoglobulin therapy and successful treatment with rituximab. Int J Dermatol. 2013;52:501–2.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, 33156, USA

    Kyle T. Amber MD

  2. Department of Dermatology and Allergology, Philipps-University, Marburg, 35043, Germany

    Rüdiger Eming MD & Michael Hertl MD

Authors
  1. Kyle T. Amber MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rüdiger Eming MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Hertl MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kyle T. Amber MD .

Editor information

Editors and Affiliations

  1. Department of Dermatology and Allergy, Center of Translational Medicine, University of Bonn, Bonn, Germany

    Thomas Bieber

  2. St. John's Institute of Dermatology, London, United Kingdom

    Frank Nestle

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Amber, K.T., Eming, R., Hertl, M. (2015). Bullous Diseases: Old Blisters with New Therapeutic Targets. In: Bieber, T., Nestle, F. (eds) Personalized Treatment Options in Dermatology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45840-2_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-45840-2_10

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-45839-6

  • Online ISBN: 978-3-662-45840-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation